Opaganib Reduces Mortality in Hospitalized COVID-19 PatientsÂ
Data from a post hoc analysis of a phase 2/3 study of oral opaganib in COVID-19 pneumonia showed a 62% reduction in mortality and a 21% improvement in time to room air.
Data from a post hoc analysis of a phase 2/3 study of oral opaganib in COVID-19 pneumonia showed a 62% reduction in mortality and a 21% improvement in time to room air.
A machine learning model has been developed by researchers to determine personalized oxygenation targets for mechanically ventilated patients.Â
Smart infant monitoring company Owlet announced the launch of Dream Sock and BabySat, two medical devices with recent FDA clearances.